Clodronate Injections for Bone Health / Mobility

For Horses

To alleviate clinical lameness in the forelimbs associated with bone resorption processes in the distal sesamoid bone (navicular bone) in adult horses.

Active Ingredient: Clodronic Acid

Package Sizes: Solution with a concentration of 51 mg/ml for injection in a 15 ml glass vial.

Indications for Use: Osphos® is an injectable bisphosphonate indicated for the control of clinical signs associated with navicular syndrome in horses aged 4 years and older. Osphos® is the only bisphosphonate approved by the FDA for intramuscular use in horses. Clodronate, the active ingredient in Osphos®, is a bisphosphonate known in laboratory animal studies and in vitro studies to inhibit bone resorption by reducing the number of active osteoclasts, regardless of the cause of osteoclast activity, and it also inhibits the formation and dissolution of calcium phosphate crystals in the bone matrix.

Dosage: Administer 1.8 mg/kg via intramuscular injection (IM) with a maximum of 900 mg per horse. The total volume is divided equally into three separate injection sites.

Storage:  Store at a temperature below 25°C in a cool, dry place. Any unused portion of the vial should be discarded as Osphos® does not contain a preservative.